Skip to main navigation
  • Investor Home
  • News & Presentations
    News Events Presentations
  • Governance
    Governance Overview Board of Directors Leadership Our ESG Philosophy
  • Financials
    SEC Filings Quarterly Results Annual Reports
  • Stock Information
    Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
  • Resources
    Pipeline Investor FAQs Email Alerts Contact IR

News Releases


Jan 14, 2024

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously

Read More

Jan 14, 2024

Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% Accord

Read More
  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
Displaying 55 - 56 of 56
Print Page
RSS Feeds
Email Alerts
Search
Arcutis Biotherapeutics logo

© 2024 Arcutis Biotherapeutics, Inc. All rights reserved.

  • Image of the Linkedin Logo
  • Image of the Twitter Logo
  • Image of the Instagram Logo
  • Contact
  • Legal Disclaimer
  • Privacy Notice
  • Consumer Health Data Privacy Policy
  • Cookies Settings

© 2024 Arcutis Biotherapeutics, Inc. All rights reserved.